Search Results
Sep 02, 2026, 06:30 ET Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it will host
More news about: Immunic, Inc.
Sep 01, 2026, 06:30 ET Immunic Appoints Chitrang Davé as Chief Data and Digital Officer
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of
More news about: Immunic, Inc.
Aug 11, 2026, 06:30 ET Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today reported financial results for
More news about: Immunic, Inc.
Aug 10, 2026, 16:05 ET Immunic Appoints Elena Ridloff to Board of Directors
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Elena
More news about: Immunic, Inc.
Jul 09, 2026, 06:30 ET Immunic to Participate in Investor Conferences in July
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the
More news about: Immunic, Inc.
Jun 10, 2026, 06:30 ET Immunic to Participate in Investor, Industry and Scientific Conferences in June
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the
More news about: Immunic, Inc.
May 28, 2026, 06:30 ET Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the presentation of
More news about: Immunic, Inc.
May 27, 2026, 06:30 ET Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of
More news about: Immunic, Inc.
May 19, 2026, 06:30 ET Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of
More news about: Immunic, Inc.
May 13, 2026, 06:30 ET Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced financial results for
More news about: Immunic, Inc.
Apr 30, 2026, 06:30 ET Immunic to Participate in Investor and Medical Conferences in May
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the
More news about: Immunic, Inc.
Apr 28, 2026, 06:30 ET Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of
More news about: Immunic, Inc.
Apr 23, 2026, 08:00 ET Immunic, Inc. Announces 1-for-10 Reverse Stock Split
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases (the "Company" or "Immunic"), today
More news about: Immunic, Inc.
Apr 09, 2026, 06:30 ET Immunic to Participate in Scientific and Medical Conferences in April
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the
More news about: Immunic, Inc.
Apr 01, 2026, 06:30 ET Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it received
More news about: Immunic, Inc.
Mar 31, 2026, 06:30 ET Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Jon
More news about: Immunic, Inc.
Mar 10, 2026, 06:30 ET Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced
More news about: Immunic, Inc.
Mar 03, 2026, 06:30 ET Immunic to Participate in Investor Conferences in March
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced participation
More news about: Immunic, Inc.
Feb 26, 2026, 06:30 ET Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced
More news about: Immunic, Inc.
Feb 17, 2026, 16:05 ET Immunic Announces Closing of Oversubscribed Private Placement Financing
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced
More news about: Immunic, Inc.
Feb 13, 2026, 06:30 ET Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced
More news about: Immunic, Inc.
Feb 04, 2026, 06:30 ET Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced
More news about: Immunic, Inc.
Jan 07, 2026, 06:30 ET Immunic Highlights 2025 Accomplishments and Upcoming Milestones
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today highlighted
More news about: Immunic, Inc.
Nov 26, 2025, 06:30 ET Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced that
More news about: Immunic, Inc.
Nov 13, 2025, 06:30 ET Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced
More news about: Immunic, Inc.